NYU Langone Post-COVID Registry
This is an observational registry study with medical record review to assess characteristics, management, and outcomes of patients who received a diagnosis of COVID-19. We plan to review baseline characteristics, clinical presentation, management and outcomes of patients who present to NYU Langone Health for post-COVID treatment. Using the data abstracted from the medical record, we will use this as a pool for future COVID-19 research study participants. The database of subject data will be supplemented with blood samples collected via the NYU Universal Consent (s16-00122, PI: Moreira). Future studies will be conducted under separate IRB protocols.
A SINGLE-CENTER OBSERVATIONAL STUDY OF CLINICAL OUTCOMES FOLLOWING TREATMENT OF LEIOMYOMA WITH COMBINATION THERAPY UTILIZING GNRH ANALOGS AND TRANSCERVICAL FIBROID ABLATION
This is a prospective cohort study of patients who will receive TFA following medical therapy for fibroid care between 1/2023 and 1/2024 at our institution. Clinical variables of interest will be collected by chart review by the study team and will include characteristics of fibroids including diameter, location and volume, volume of uterus, medical management prior to TFA, need for surgical reintervention within 6-12 months following TFA due to heavy menstrual bleeding, and ultrasound and lab data prior to TFA and at 3, 6 and 12 months post procedure. Additional quality of life data collected by surveys will be summarized at all specified time points.
Genetic evaluation of patients with undiagnosed diseases
The purpose of this study is to use extensive sequencing of the DNA (genetic material inherited from parents) or RNA (transcripts of the DNA), and functional characterization of patient-derived cells if necessary, to identify the cause of an individual's undiagnosed medical condition. Today, advances in technology allow us to sequence all the portions of the DNA containing instructions for the proteins in the body (whole exome sequencing, abbreviated WES), all of a person's DNA (called whole genome sequencing, abbreviated WGS), or RNA (called RNA-sequencing, abbreviated RNA-seq). WES, WGS, and RNA-seq have been used recently to make diagnoses for individuals suffering from diseases that doctors cannot figure out but seem to be due to errors in the DNA. Generally, the doctors first order many conventional medical tests, including some more limited DNA sequencing tests, before resorting to WES or WGS. For this study, we intend to use WES, WGS and/or RNA-seq as one of the first tests for individuals suffering from problems that suggest that they might be caused by errors in the DNA. The purpose is to provide diagnoses to patients with undiagnosed disease, find out how often we can make a diagnosis in this way, see if we can arrive at that answer more rapidly, and what effect finding a diagnosis has on a patient's medical care and well-being.
Global Pediatric Orthopedic Implant Safety & Efficacy (Global POISE) Clinical Follow-Up Program
The purpose of this research study is to evaluate the safety and efficacy (how well they do their job) of OrthoPediatrics medical implants.
Mechanisms of Peripheral Vascular Disease
The proposed study will enable the use of human tissue samples and outcome data by basic and clinical investigators for research into the biology, causes, prevention and therapy of patients with documented peripheral arterial vascular disease secondary to atherosclerosis. The collection of paired information will provide important clinically relevant findings that will add to the growing understanding of the natural history of plaque formation in the arteries of the periphery and will enable to decipher the molecular mechanisms in this pathology. We will prospectively collect both tissue to study the mechanism of the natural history of PAD. We will also collect relevant clinical and medical information on these subjects and continue to collect follow-up information on the surgical patients using their medical records in order to follow their outcome.
Mobilis Laboratory Subject Registry
The Mobilis Laboratory Subject Registry is a tool used to recruit healthy individuals and those with stroke for IRB-approved studies. The Registry will include circumscribed demographic and medical information on enrolled participants.
Distal Ischemic Stroke Treatment with Adjustable Low-profile Stentriever
Evaluate the safety and effectiveness of the treatment with the investigational Tigertriever 13 device as compared to standard medical management.
Mechanisms of Vascular Aneurysms
Our mission is to enable the use of human tissues with outcome data by basic and clinical investigators for research into the biology, causes, prevention and therapy of patients with documented arterial pathology (e.g. aortic dissection, lower extremity aneurysm, aortic aneurysm). Paired clinical information about disease history and research into vascular events will enable clinically relevant findings. We will prospectively collect both tissue samples and blood samples to study the mechanisms of the natural history of aneurysms and potential circulating biomarkers. We will be collaborating with Dr. Gelb in order to obtain tissue and blood from healthy controls during the organ procurement. We will also collect relevant clinical and medical information on these subjects and continue to collect follow-up information on the surgical patients using their medical records in order to follow their outcome. The tissue and blood will be stored indefinitely.
The (IRAD) International Registry for Acute Aortic Dissection
The purpose of this study is to collect information regarding your medical condition for a registry. The aim of the registry is to document a few important medical details of patients like you who were hospitalized for an acute aortic dissection. An aortic dissection is a serious condition in which a tear occurs in the inner layer of the body's main artery (aorta). Blood rushes through the tear, causing the inner and middle layers of the aorta to split (dissect). Based on the rarity of this disease and few guidelines regarding the most effective treatment for this disease, this registry aims to collect information from patients like you to study this disease. Patients from various hospitals in this country and in several other countries are being asked to participate. This information will help doctors understand more about acute aortic dissection. We believe this information will help to improve the treatment of patients like you in the future.
A sham-controlled pilot trial of focused ultrasound modulation of the globus pallidus interna in schizophrenia
The primary objectives of this study are to examine the tolerability of pulsed low-intensity focused ultrasound (PLIFUS) and its effects on brain function measured via fMRI functional connectivity and symptom response in individuals with schizophrenia. A neuronavigated single-element piezoelectric device will be utilized to noninvasively deliver transcranial PLIFUS sonication to the right globus pallidus interna, a brain region implicated in schizophrenia. We aim to enroll N=12 participants with schizophrenia in a random order, sham-controlled crossover trial of a single session of PLIFUS counterbalanced with a single sham sonication session, one week apart. After the participant provides written informed consent, a medical and psychiatric evaluation will be performed to determine eligibility for inclusion in the study, followed by a structural MRI to guide neuro-navigation. The first intervention visit will include a 10 minute PLIFUS sonication or sham sonication, preceded and followed by fMRI and an exit medical examination. Psychiatric symptoms will be assessed immediately prior to sonication/sham, during sonication/sham and 5 minutes, 30 minutes, 60 minutes, 1 day and 7 days after sonication/sham. The second intervention visit will consist of sonication or sham preceded and followed by fMRI in addition to symptom assessments and post-sonication/sham medical evaluation. Participants will be closely monitored during and after procedures for tolerability and adverse effects, including 1 and 7 day follow-up visits. The goal of this pilot study is to establish feasibility and tolerability and to determine whether the sonication procedure produces effects on the imaging biomarker and on symptoms prior to proceeding to therapeutic trials using repeated administration. If PLIFUS effects on fMRI and symptom ratings are not detected in the first 4 completers, subsequent participants will receive 3 sessions over 5 days.